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ABSTRACT
Introduction: Patients with type 2 diabetes
mellitus (T2DM) must remain adherent and
persistent on antidiabetic medications to
optimize clinical benefits. This analysis
compared adherence and persistence among
adults initiating dipeptidyl peptidase-4
inhibitors (DPP-4is), sulfonylureas (SUs), and
thiazolidinediones (TZDs) and between patients
initiating saxagliptin or sitagliptin, two DPP-4is.
Methods: This retrospective cohort study
utilized the US MarketScan (Truven Health
Analytics, Ann Arbor, MI, USA) Commercial
and Medicare Supplemental health insurance
claims databases. Adults aged C18 years with
T2DM who initiated a DPP-4i, SU, or TZD from
January 1, 2009 to January 31, 2012 were
included. Patients must have been
continuously enrolled for C1 year prior to and
C1 year following initiation. Adherence was
measured using proportion of days covered
(PDC), with PDC C 0.80 considered adherent.
Persistence was measured as time to
discontinuation, defined as last day with drug
prior to a 60? days gap in therapy.
Multivariable logistic regression and Cox
proportional hazards models compared the
outcomes between cohorts, controlling for
baseline differences.
Results: The sample included 238,372 patients
(61,399 DPP-4i, 134,961 SU, 42,012 TZD).
During 1-year follow-up, 47.3% of DPP-4i
initiators, 41.2% of SU initiators, and 36.7% of
TZD initiators were adherent. Adjusted odds of
adherence were significantly greater among
DPP-4i initiators than SU (adjusted odds ratio
[AOR] = 1.678, P\0.001) and TZD initiators
(AOR = 1.605, P\0.001). During 1-year
follow-up, 55.0% of DPP-4i initiators, 47.8% of
SU initiators, and 42.9% of TZD initiators did
not discontinue therapy. Adjusted hazards of
discontinuation were significantly greater for
SU (adjusted hazard ratio [AHR] = 1.390,
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P\0.001) and TZD initiators (AHR = 1.402,
P\0.001) compared with DPP-4i initiators.
Saxagliptin initiators had significantly better
adherence (AOR = 1.213, P\0.001) compared
with sitagliptin initiators, and sitagliptin
initiators had significantly greater hazard of
discontinuation (AHR = 1.159, P\0.001).
Results were similar over a 2-year follow-up.
Conclusions: US adults with T2DM who
initiated DPP-4i therapy, particularly
saxagliptin, had significantly better adherence
and persistence compared with patients who
initiated SUs or TZDs.
Keywords: Adherence; Dipeptidyl peptidase-4
inhibitors; Persistence; Type 2 diabetes mellitus
INTRODUCTION
In the US, an estimated 26 million people have
diabetes, approximately 8% of the entire
population [1]. Diabetic complications are an
important medical and public health concern,
as diabetes is associated with kidney failure,
limb amputation, blindness, heart disease, and
stroke [1]. Appropriate disease management,
primarily maintenance of glycated hemoglobin
(HbA1c) levels below 7% can decrease the risk of
microvascular complications [2]. Current
treatments for type 2 diabetes mellitus (T2DM)
include lifestyle and dietary modifications, oral
antidiabetic medications, non-insulin
injectables, and insulin [2, 3]. For patients
with mild hyperglycemia, lifestyle change and
monotherapy with metformin or an acceptable
alternative, such as a dipeptidyl peptidase-4
inhibitor (DPP-4i), are recommended [3].
Sulfonylureas (SUs) and thiazolidinediones
(TZDs) can also be prescribed, although it has
been suggested that the additional risks
associated with these drug classes should be
considered [3]. The American Diabetes
Association, European Association for the
Study of Diabetes, and the American
Association of Clinical Endocrinologists
recommend that patients who do not reach
HbA1c targets should be prescribed
combination therapy, followed by insulin
initiation if necessary [2, 3].
To optimize the clinical benefits of
antidiabetic pharmacotherapy, patients must
remain adherent to and persistent with their
prescribed medications. The importance of
adherence to antidiabetic medications has
been recognized by Medicare and appears as a
Medicare Part D plan quality measure [4].
Increased adherence to medications is
associated with a decrease in HbA1c [5–8],
lower odds of mortality [7], fewer all-cause
hospitalizations [7], and lower healthcare
expenditures [9–12]. These improvements in
outcomes may translate into substantial benefit
to the healthcare system, averting a projected
699,000 emergency room visits and 341,000
hospitalizations per year, resulting in a savings
of nearly $5 billion [13]. Despite the noted
impact of good adherence, a systematic review
found a wide range of adherence rates across
retrospective studies, with rates ranging from
36% to 93% [14]. A second review found that
when combining study results, only 58% of
patients were considered adherent [15]. To date,
the majority of interventions to improve
adherence to diabetes medications have
focused on education and one-on-one
counseling [16].
Several factors associated with adherence to
antidiabetic medications have been identified
in the literature. Younger age, female gender,
residence in the Southern region of the US, and
high cost-sharing have been associated with
lower adherence in multiple analyses [10, 17,
18]. Additional factors include depression,
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polytherapy, and twice-daily regimens [14].
Analyses have also compared patients
initiating specific non-insulin antidiabetic
drugs and drug classes in terms of adherence
and persistence, including metformin, SUs,
glucagon-like peptide-1 receptor agonists (GLP-
1RAs), TZDs, and DPP-4is [10, 17, 19, 20].
To our knowledge, no US-based analyses
comparing adherence to and persistence with
DPP-4is as a medication class with other classes
of antidiabetic medications have been reported.
Therefore, the objective of this analysis was to
compare adherence and persistence among
patients initiating DPP-4is, SUs, and TZDs over
1- and 2-year follow-up periods. Additional
objectives were to compare adherence and
persistence between patients initiating
saxagliptin and sitagliptin and to describe
treatment patterns following initiation.
METHODS
Data Source
This retrospective, observational cohort study
used administrative claims data from the
Truven Health MarketScan (Truven Health
Analytics, Ann Arbor, MI, USA) Commercial
and Medicare Supplemental databases. The
databases contain inpatient medical,
outpatient medical, and outpatient
prescription administrative claims data and
enrollment records of individuals with
employer-sponsored primary or Medicare
supplemental insurance. The Commercial and
Medicare Supplemental Databases have been
utilized in numerous published analyses [21].
The data were previously collected, de-
identified, and compliant with the Health
Insurance Portability and Accountability Act
privacy regulations. Therefore, Institutional
Review Board approval and written informed
consent were not required for this study.
Patient Selection
Patients with at least one outpatient pharmacy
claim with a National Drug Code (NDC) for a
DPP-4i, SU, or TZD from January 1, 2009 to
January 31, 2012, were selected. A rolling
selection method was used, whereby each drug
claim was evaluated on the criteria described
below and the earliest claim meeting all criteria
was selected as the index date and the medication
class (DPP-4i, SU, or TZD) was considered the
index drug class. Patients must have had at least
28 days of continuous supply of the index drug
class and have been at least 18 years old on the
index date. All patients were required to have at
least 365 days of continuous enrollment with
medical and pharmacy benefits prior to the index
date (pre-period) and at least 365 days of
enrollment following the index date (1-year
follow-up period). A subset of patients was
required to have 730 days of post-index
enrollment (2-year follow-up period). To
capture initiators only, patients were required to
have no claims for the index drug class in the pre-
period. Lastly, patients were required to have at
least one non-diagnostic medical claim with a
T2DM diagnosis (International Classification of
Diseases, Ninth Revision, Clinical Modification
[ICD-9-CM] 250.x0, 250.x2) during the study
period. Patients with medical claims with
diagnoses of type 1 diabetes (ICD-9-CM 250.x1,
250.x3) or gestational diabetes (ICD-9-CM
648.8x) or with multiple index drug classes on
index date were excluded from analysis.
Outcome Variables
The primary outcomes were adherence to and
persistence with the index drug class. Both
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measures were calculated using the service date
and days’ supply fields existing on outpatient
pharmacy claims for DPP-4is, SUs, and TZDs
identified by NDC codes. Adherence was
measured as proportion of days covered (PDC),
calculated by taking the number of days a
patient had the index drug class on hand
during the 1- or 2-year follow-up based on the
days’ supply field on pharmacy claims divided
by follow-up time (365 or 730 days). Days’
supply for early refills was appended to the
end of days’ supply of the previous prescription.
Patients with a PDC C 0.80 were considered
adherent. Persistence was defined as the time
from index date to last day with index drug
class on hand prior to a gap of [60 consecutive
days without index drug class [22]. A cut-point
of 60 days was utilized as a conservative
definition of discontinuation, as patients with
gaps of up to 60 days were considered
persistent. Switching within drug class was
allowed for the drug class comparison. When
comparing adherence and persistence outcomes
between patients initiating saxagliptin and
sitagliptin, PDC and time to discontinuation
were calculated at the drug level, rather than
the drug class level.
Patients were classified into the following
mutually exclusive groups based on first event
after index date during the 1-year follow-up
period: remained on index drug class with no
augmentation, augmentation with additional
drug class, discontinuation of index drug class
and switch to a new drug class, discontinuation
of study drug class and continuation on other
medication classes with no switch, and
discontinuation of all antidiabetic
medications. An augmentation was defined as
the addition of a medication class not part of
the initial regimen that overlapped with the
index drug class for [30 days. A switch was
defined as the discontinuation of index drug
class and the addition of medication class not in
the initial regimen prior to discontinuation
with overlap B30 days or following
discontinuation. Discontinuation was
measured at the drug class level for all cohort
comparisons.
Independent Variables
The primary independent variable of interest
was index drug class: DPP-4i, SU, or TZD. When
comparing within the DPP-4i medication class,
the primary predictor was index drug:
saxagliptin or sitagliptin. A third DPP-4i,
linagliptin, was not compared within the DPP-
4i–specific analysis because few linagliptin
initiators had 1 year of follow-up, and no
linagliptin initiators had 2 years of follow-up
in the claims data. A fourth DPP-4i, alogliptin,
was not available in the US during the patient
selection period.
Demographic, clinical, and cost and
utilization characteristics were measured to
describe the study sample and to control for
potential confounding in multivariable models.
Demographic measures included: sex, age,
geographic region, urbanicity, insurance plan
type, primary payer, presence of capitated
services, and year of index date. Clinical
characteristics were measured during the pre-
period and included use of study drugs other
than index drug class, and metformin and
insulin use based on pharmacy claims, overall
health captured by the Deyo Charlson
Comorbidity Index (CCI) [23] and the number
of unique ICD-9-CM codes appearing on a
patient’s medical claims, diagnosis of
macrovascular disease (acute myocardial
infarction, other ischemic heart disease,
congestive heart failure, cerebrovascular
accident, or peripheral vascular disease) and
microvascular disease (diabetic peripheral
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neuropathy, diabetic retinopathy, leg and foot
amputation, or nephropathy), and diagnosis or
procedure indicative of renal impairment.
Pregnancy during the follow-up period was
captured, as it may affect diabetes treatment.
Cost and utilization covariates captured during
the pre-period were evidence of an
endocrinologist visit and cardiologist visit,
total healthcare expenditures, and diabetes
prescription expenditures.
Several characteristics of the index drug
prescription claim were also captured: the
days’ supply, mail-order status, fixed-dose
combination with metformin, cost-sharing
index, which was the average patient out-of-
pocket cost for a 30-day supply, calculated
annually for each study drug for each
insurance plan in the database, and index
regimen [24]. A patient’s initial regimen was
defined as the index drug class plus any
concomitant use of additional antidiabetic
medication classes (alpha-glucosidase
inhibitors, amylin analogs, dopamine receptor
agonists, GLP-1RAs, insulin, meglitinides, and
metformin). Claims with service dates occurring
60 days prior to the index date to 45 days after
were evaluated. A medication class was
considered part of the initial regimen if (a) the
patient received a prescription for the drug class
within 60 days before index date and received a
second prescription for that drug class within
45 days after index date or (b) the patient
received a prescription for the drug within
60 days before index date or 45 days after
index date and had C30 days’ overlap between
index drug class and additional drug class
between index date and index date ? 45 days.
This definition was purposely conservative so as
not to misclassify switches as part of a patient’s
initial regimen. Patients with no additional
medication classes meeting this definition
were considered to be on monotherapy.
Analysis
In descriptive analyses, pairwise comparisons
using t tests and Chi-squared tests were
conducted comparing SU initiators and TZD
initiators with DPP-4i initiators and saxagliptin
initiators with sitagliptin initiators.
Multivariable logistic regression models were
fit to compare the odds of being adherent, and
multivariable Cox proportional hazards models
were fit to compare time to discontinuation
(persistence) between index drug classes and
index drugs. To determine which covariates
were included in the multivariable models,
descriptive statistics and statistical tests were
evaluated to identify characteristics that
differed between cohorts and also may be
associated with adherence or persistence (i.e.,
were potential confounders). Models controlled
for the following variables: age, sex, presence of
capitated services, payer, region, urbanicity,
plan type, indicator for fixed-dose metformin
index drug, indicator for index drug filled via
mail order, index drug regimen (monotherapy,
index drug plus additional non-insulin
antidiabetic drugs, index drug plus insulin),
baseline total expenditures and diabetes
prescription expenditures, index diabetes
medication class cost-sharing, baseline
endocrinologist and cardiologist visits,
baseline renal impairment, baseline
macrovascular and microvascular disease,
pregnancy during follow-up, baseline number
of unique three-digit ICD-9-CM diagnoses and
Charlson Comorbidity Index. Sensitivity
analyses of monotherapy and non-mail-order
patients were also conducted, as patients
initiating monotherapy have the simplest
treatment profile and those with an initial
prescription filled via mail order may have
inflated persistence due to larger days’ supply
on the index claim and automatic refill. P values
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were compared with an a priori alpha 0.05 to
determine statistical significance. Analyses were
conducted with SAS version 9.3 (SAS Institute
Inc. Cary, NC, USA).
RESULTS
Patient Selection
Patient attrition is presented in Fig. 1. There
were 1,788,908 patients identified from the
databases with at least one prescription claim
for a DPP-4i, SU, or TZD from January 1, 2009 to
January 31, 2012. After applying additional
inclusion and exclusion criteria, the final
sample consisted of 238,372 patients; 61,399
patients initiated a DPP-4i, 134,961 initiated an
SU, and 42,012 initiated a TZD. Within DPP-4i
initiators, 11,219 patients initiated saxagliptin
and 49,400 initiated sitagliptin. A total of
134,444 patients had 2 years of follow-up data.
Descriptive Analysis
Demographic, clinical, and treatment
characteristics are presented in Tables 1 and 2.
The average age of patients in the sample was
56.7 years (standard deviation [SD] 12.2), and
54.3% were men. The majority of patients were
insured through a commercial plan (77.7%).
Approximately, one-fifth (20.3%) had evidence
of macrovascular disease in the pre-period.
Metformin use was common in the pre-period
(55.0%), whereas insulin use was less common
(6.7%). There were significant differences in
baseline characteristics among the three drug
class cohorts. DPP-4i initiators were younger on
average than SU initiators but older than TZD
initiators, and a greater proportion were women
than both SU and TZD initiators. The
proportion of patients using metformin in the
pre-period was higher among DPP-4i initiators,
and a greater proportion of patients initiated a
study drug that was part of a fixed-dose
combination with metformin. A mail-order
index prescription was more common among
DPP-4i initiators, whereas initiating
monotherapy was less common. Significant
differences were also found between the
saxagliptin and sitagliptin initiators. On
average, saxagliptin initiators were younger
and more commonly insured through
commercial plans. The prevalence of renal
impairment, macrovascular disease, and
microvascular disease was lower among
saxagliptin initiators. More saxagliptin
initiators initiated monotherapy compared
with sitagliptin initiators.
Figure 2 presents treatment patterns
following index drug class initiation. Among
all study cohorts, augmentation was the least
common event, although augmentation was
more common among DPP-4i initiators. A
significantly larger proportion of DPP-4i
initiators remained on index drug class
compared with SU and TZD initiators. Among
DPP-4i initiators, the proportion of patients
remaining on DPP-4is was significantly larger
among the saxagliptin initiators. Overall, 20.6%
of the study sample discontinued all
antidiabetic medications for [60 days without
first switching or augmenting. Discontinuing all
antidiabetic medications was least common
among DPP-4i initiators because, as noted
above, remaining on initial regimen or
augmenting was more common. In the DPP-
4i-specific comparison, discontinuing all
antidiabetic medications was less common
among saxagliptin initiators. Within the first
year, over 40% of SU and TZD initiators stopped
refilling their index drug class, either
discontinuing all antidiabetic medications or
1292 Adv Ther (2014) 31:1287–1305
continuing on the other medications in their
initial regimen.
Unadjusted adherence and persistence
results are presented in Table 3. Over the
1-year follow-up period, a significantly greater
proportion of DPP-4i initiators were adherent to
index drug class than SU and TZD initiators.
This relationship was consistent over the 2-year
follow-up period and in the monotherapy and
the non-mail-order sub-samples. Significantly
more DPP-4i initiators were persistent with
index drug class during the 1-year follow-up
period than SU initiators and TZD initiators. As
with adherence, this was true over the 2-year
Fig. 1 Patient attrition. DPP-4i Dipeptidyl peptidase-4 inhibitor, ICD-9-CM International Classiﬁcation of Diseases,
Ninth Revision, Clinical Modiﬁcation, SU Sulfonylurea, TZD Thiazolidinedione
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follow-up period and in both sub-samples.
Among DPP-4i initiators, patients initiating
saxagliptin had better unadjusted persistence
to index drug than patients initiating sitagliptin
overall and in sub-samples. There were
significant differences in adherence between
the two cohorts in all samples except
monotherapy patients. Descriptively, a smaller
proportion of linagliptin patients were adherent
(43.5%) compared with saxagliptin patients
(49.1%) and sitagliptin patients (46.1%) and a
smaller proportion of linagliptin patients were
persistent (50.9% vs. 56.6% for saxagliptin and
53.6% for sitagliptin) during the first year of
follow-up. No statistical comparisons were
conducted due to small sample size.
Multivariable Analysis
Figure 3 presents adherence results. In adjusted
logistic regression models, patients initiating
DPP-4is had significantly greater odds of being
adherent than patients initiating an SU or TZD.
During the 1-year follow-up period, the
adjusted odds of being adherent among DPP-4i
initiators was over 1.6 times the odds of being
adherent among SU initiators (adjusted odds
ratio [AOR] = 1.678, 95% confidence interval
[CI] = 1.631, 1.727) and TZD initiators
(AOR = 1.605, 95% CI = 1.563, 1.647). Among
DPP-4i initiators, patients initiating saxagliptin
had significantly greater odds of being adherent
than patients initiating sitagliptin
(AOR = 1.213, 95% CI = 1.161, 1.266). Results
for the 2-year follow-up period and for subsets
of monotherapy and non-mail-order patients
were of similar direction, magnitude, and
significance.
Figures 4 and 5 present adjusted curves for
time to discontinuation. In adjusted Cox
proportional hazards models, the adjusted
hazard of discontinuation was approximately
40% higher among SU initiators (adjusted
hazard ratio [AHR] = 1.390, 95% CI = 1.363,
1.418) and TZD initiators (AHR = 1.402, 95%
CI = 1.377, 1.427) compared with DPP-4i
initiators during 1-year follow-up. Over the
same time period, patients who initiated
sitagliptin were significantly more likely to
discontinue than those who initiated
Fig. 2 First treatment event after index drug class/index
drug initiation. P values for comparing DPP-4i and SU
initiators, DPP-4i and TZD initiators, and saxagliptin and
sitagliptin initiators were \0.001. Discontinuation
([60 days without drug on hand) was measured at drug
class level for all cohorts. DPP-4i Dipeptidyl peptidase-4
inhibitor, SU Sulfonylurea, TZD Thiazolidinedione
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saxagliptin (AHR = 1.159, 95% CI = 1.122,
1.195). As with adherence, these associations
held over the 2-year follow-up period and
within the two patient subgroups.
DISCUSSION
In this US administrative claims-based analysis
of adults with T2DM, patients who initiated a
DPP-4i had significantly better adherence to
and persistence with index drug class
compared with patients who initiated an SU
or TZD. Among DPP-4i initiators, saxagliptin
patients had significantly better adherence
and persistence than sitagliptin patients.
These associations were observed over a
1-year follow-up period, a 2-year follow-up
period, and within sub-samples of patients
initiating monotherapy and filling index
prescription through a non-mail-order
method.
Patients may discontinue their oral
antidiabetic medication following the onset of
adverse events particular to their medication,
Fig. 3 Adjusted odds ratio for being adherent
(PDC C 0.80) by index drug class and index drug within
DPP-4i cohort for 1- and 2-year follow-up among full study
sample and sub-samples of monotherapy and non-mail-
order patients. Models controlled for age, sex, presence of
capitated services, payer, region, urbanicity, plan type,
indicator for ﬁxed-dose metformin index drug, indicator for
index drug ﬁlled via mail order, index drug regimen
(monotherapy, index drug plus additional non-insulin
antidiabetic drugs, index drug plus insulin), baseline total
expenditures and diabetes prescription expenditures, index
diabetesmedication class cost-sharing, baseline endocrinologist
and cardiologist visits, baseline renal impairment, baseline
macrovascular and microvascular disease, pregnancy during
follow-up, baseline number of unique 3-digit ICD-9
diagnoses and Charlson Comorbidity Index. AOR Adjusted
odds ratio, CI Conﬁdence interval, DPP-4i Dipeptidyl
peptidase-4 inhibitor, PDC Proportion of days covered, SU
Sulfonylurea, TZD Thiazolidinedione
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such as hypoglycemia while on an SU [25, 26].
Additionally, clinicians may discontinue a
medication when the patient develops a
comorbidity that places the patient at greater
risk for an adverse event with a particular
medication, for example, a patient at
increasing risk for fractures on a TZD [27].
Potential explanations for the observed
association between initiation of DPP-4is and
better adherence and persistence include a
better tolerability profile compared with SUs,
which are associated with weight gain and
hypoglycemia, and TZDs, which are associated
with weight gain and bone fracture [3].
Fig. 4 Adjusted curves for time to discontinuation by
index drug class for 1- and 2-year follow-up and within sub-
samples of monotherapy and non-mail-order patients for
1-year follow-up. a Adjusted curves and hazard ratios for
discontinuation of index drug class over 1-year follow-up
period. b Adjusted curves and hazard ratios for
discontinuation of index drug class over 2-year follow-up
period. c Adjusted curves and hazard ratios for
discontinuation of index drug class over 1-year follow-up
period among monotherapy patients. d Adjusted curves and
hazard ratios for discontinuation of index drug class over
1-year follow-up period among non-mail-order patients.
Models controlled for age, sex, presence of capitated
services, payer, region, urbanicity, plan type, indicator for
ﬁxed-dose metformin index drug, indicator for index drug
ﬁlled via mail order, index drug regimen (monotherapy,
index drug plus additional non-insulin antidiabetic drugs,
index drug plus insulin), baseline total expenditures
and diabetes prescription expenditures, index diabetes
medication class cost-sharing, baseline endocrinologist and
cardiologist visits, baseline renal impairment, baseline
macrovascular and microvascular disease, pregnancy during
follow-up, baseline number of unique 3-digit ICD-9
diagnoses and Charlson Comorbidity Index. AHR
Adjusted hazard ratio, CI Conﬁdence interval, DPP-4i
Dipeptidyl peptidase-4 inhibitor, SU Sulfonylurea, TZD
thiazolidinedione
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Differences noted between saxagliptin and
sitagliptin may be due in part to a one-step
dose adjustment for patients with renal
impairment for saxagliptin, compared with a
two-step dose adjustment for sitagliptin [28,
29]. However, more research utilizing
additional types of data sources is needed to
specifically test these hypotheses for the
differences in adherence and persistence
between drug classes and DPP-4i-specific drugs.
An analysis conducted by Rathmann et al.
[20] comparing DPP-4is and SUs reported results
consistent with the findings presented here.
Utilizing data from general practices in
Germany, researchers found that the risk of
discontinuation was higher for DPP-4i initiators
Fig. 5 Adjusted curves for time to discontinuation by
index drug for 1- and 2-year follow-up and within sub-
samples of monotherapy and non-mail-order patients for
1-year follow-up. a Adjusted curves and hazard ratios for
discontinuation of index drug over 1-year follow-up period.
b Adjusted curves and hazard ratios for discontinuation of
index drug over 2-year follow-up period. c Adjusted curves
and hazard ratios for discontinuation of index drug over
1-year follow-up period among monotherapy patients.
d Adjusted curves and hazard ratios for discontinuation
of index drug over 1-year follow-up period among non-
mail-order patients. Models controlled for age, sex, presence
of capitated services, payer, region, urbanicity, plan type,
indicator for ﬁxed-dose metformin index drug, indicator for
index drug ﬁlled via mail order in monotherapy samples,
index drug regimen (monotherapy, index drug plus
additional non-insulin antidiabetic drugs, index drug plus
insulin) in non-mail-order samples, baseline total
expenditures and diabetes prescription expenditures,
index diabetes medication class cost-sharing, baseline
endocrinologist and cardiologist visits, baseline renal
impairment, baseline macrovascular and microvascular
disease, pregnancy during follow-up, baseline number of
unique 3-digit ICD-9 diagnoses and Charlson Comorbidity
Index. AHR Adjusted hazard ratio, CI Conﬁdence interval,
DPP-4i Dipeptidyl peptidase-4 inhibitor
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in the first 3 months and then fell below that of
SU initiators for the remainder of follow-up, a
maximum of 2 years [20]. Using US health
insurance claims, Curkendall et al. [10]
evaluated adherence and persistence over
1-year follow-up between patients initiating
saxagliptin and patients initiating an SU, TZD,
or GLP-1RA. These investigators found that
patients initiating saxagliptin had greater odds
of being adherent and lower risk of
discontinuation than patients initiating
medications within the other three drug
classes [10]. No analyses over a 2-year follow-
up or within monotherapy or non-mail-order
subgroups were conducted [10]. Beyond
adherence and persistence, Rathmann et al.
[20] found that compared with SUs, initiating
a DPP-4i was associated with lower risk of
hypoglycemia and newly diagnosed
macrovascular outcomes, including coronary
heart disease, myocardial infarction, and stroke.
This study has limitations that should be
recognized. Administrative claims data are not
collected for research purposes, and the
diagnostic coding on administrative claims is
recorded by healthcare providers to support
reimbursement. Consequently, misclassification
of certain study variables, comorbid conditions in
particular, may have occurred. Similarly,
unmeasured confounding may exist, as clinical
variables such as HbA1c level and duration of
disease, socioeconomic characteristics such as
income and education, and other factors such as
provider characteristics were not available for
inclusion in the claims databases. As this was a
retrospective, observational analysis, causal
inferences should be drawn with caution.
Calculations of adherence and persistence were
based on the service date and days’ supply from
outpatient prescription drug claims and assume
that patients took the medication as directed. It
cannot be determined whether patients skipped
doses or discontinued the medication prior to the
end of the current days’ supply. Any prescriptions
obtained without generating a health insurance
claim were not captured in this analysis. The
reason for discontinuation (e.g., adverse events,
failure to achieve treatment goals, etc.) is not
available in claims databases. Lastly, the
MarketScan Commercial and Medicare
Supplemental databases contain data only on
patients covered through employers, private
commercial insurance, or employer-sponsored
supplemental Medicare. Thus, findings from the
study may not be generalizable to the whole US
Medicare population, Medicaid population, or
the uninsured.
CONCLUSIONS
Patients initiating DPP-4is were more adherent
to and persistent with the index drug class than
patients initiating SUs or TZDs. These findings
were robust to sensitivity analyses. Similarly,
patients initiating saxagliptin were more likely
to be adherent and persistent than patients
initiating sitagliptin. These associations
between DPP-4is and adherence and
persistence support the use of DPP-4i
medications, specifically saxagliptin, in
management of T2DM, as adherence and
persistence are important to experiencing
optimal clinical outcomes.
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